Ignite Creation Date:
2025-12-24 @ 7:35 PM
Ignite Modification Date:
2026-02-26 @ 12:41 AM
Study NCT ID:
NCT03228303
Status:
UNKNOWN
Last Update Posted:
2017-10-10
First Post:
2017-07-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia
Sponsor:
Assiut University
Organization:
Study Overview
Official Title:
Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia
Status:
UNKNOWN
Status Verified Date:
2017-10
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Detailed Description:
Study size is 100 patients in 2 arms 50 patients in nilotinib ttt 50 patients in imatinib ttt
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: